Optimizing Therapy for Ovarian Cancer: Recent Data Highlights

A panel of esteemed physicians review recent key data updates in ovarian cancer from ESMO 2022, including late-breaking news.

EP. 1: Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

October 6th 2022

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

EP. 2: PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

October 6th 2022

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

EP. 3: PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer

October 17th 2022

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

EP. 4: Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial

October 17th 2022

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

EP. 5: Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial

October 20th 2022

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

EP. 6: The Rationale for PARP Inhibition plus IO in Ovarian Cancer

October 20th 2022

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

EP. 7: Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment

October 27th 2022

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

EP. 8: PARP Inhibitor Resistance in Ovarian Cancer Treatment

October 27th 2022

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

EP. 9: The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer

November 4th 2022

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

EP. 10: Antibody-Drug Conjugates in Ovarian Cancer Treatment

November 4th 2022

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

EP. 11: Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer

November 10th 2022

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

EP. 12: Investigative Therapies in Recurrent Ovarian Cancer

November 10th 2022

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

EP. 13: Treatment of Rare Tumors in Ovarian Cancer

November 17th 2022

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

EP. 14: Key Data Highlights in Ovarian Cancer

November 17th 2022

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.